|24.83||-0.2600||-1.04%||Vol 171.44K||1Y Perf 262.74%|
|Jul 27th, 2021 13:16 DELAYED|
|- -%||- -|
|Target Price||27.50||Analyst Rating||Strong Buy 1.00|
|Potential %||10.62||Finscreener Ranking||★+ 44.41|
|Insiders Trans % 3/6/12 mo.||-100/-71/-71||Value Ranking||+ 38.01|
|Insiders Value % 3/6/12 mo.||-100/-7/-7||Growth Ranking||★★★+ 55.79|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-5/-5||Income Ranking||— -|
|Market Cap||1.52B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||89.33||Earnings Date||7th Sep 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||7th Sep 2021|
|Estimated EPS Next Report||0.02|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||409.33K|
|Avg. Monthly Volume||629.98K|
|Avg. Quarterly Volume||582.51K|
Avid Bioservices Inc. (NASDAQ: CDMO) stock closed at 25.09 per share at the end of the most recent trading day (a -3.28% change compared to the prior day closing price) with a volume of 354.01K shares and market capitalization of 1.52B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 227 people. Avid Bioservices Inc. CEO is Nicholas S. Green.
The one-year performance of Avid Bioservices Inc. stock is 262.74%, while year-to-date (YTD) performance is 117.42%. CDMO stock has a five-year performance of 868.73%. Its 52-week range is between 6.49 and 27.02, which gives CDMO stock a 52-week price range ratio of 89.33%
Avid Bioservices Inc. currently has a PE ratio of 648.50, a price-to-book (PB) ratio of 20.39, a price-to-sale (PS) ratio of 15.99, a price to cashflow ratio of 49.40, a PEG ratio of 2.32, a ROA of 1.73%, a ROC of -0.35% and a ROE of 5.36%. The company’s profit margin is 11.74%, its EBITDA margin is 16.50%, and its revenue ttm is $95.87 Million , which makes it $1.57 revenue per share.
Of the last four earnings reports from Avid Bioservices Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.02 for the next earnings report. Avid Bioservices Inc.’s next earnings report date is 07th Sep 2021.
The consensus rating of Wall Street analysts for Avid Bioservices Inc. is Strong Buy (1), with a target price of $27.5, which is +10.62% compared to the current price. The earnings rating for Avid Bioservices Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avid Bioservices Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avid Bioservices Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.81, ATR14 : 1.14, CCI20 : -33.81, Chaikin Money Flow : 0.10, MACD : 0.48, Money Flow Index : 42.03, ROC : -5.75, RSI : 50.36, STOCH (14,3) : 33.84, STOCH RSI : 0.00, UO : 45.05, Williams %R : -66.16), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avid Bioservices Inc. in the last 12-months were: Daniel Ryan Hart (Option Excercise at a value of $0), Daniel Ryan Hart (Sold 5 409 shares of value $138 528 ), Mark R. Bamforth (Buy at a value of $2 290 680), Mark R. Bamforth (Sold 126 000 shares of value $2 290 680 ), Mark R. Ziebell (Option Excercise at a value of $0), Mark R. Ziebell (Sold 7 207 shares of value $184 574 ), Richard B. Hancock (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.